- Relief therapeutics ceo. The company was incorporated as Relief Therapeutics Holdings AG (RFLB. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. Other executives include Marco Marotta, Chief Business Officer; Nermeen Varawalla, Chief Medical Officer and 1 others. Aug 14, 2025 · Relief Therapeutics Announces Filing of Lawsuit Against its U. 00 ( 0. See the full leadership team at Craft. End of Announcement EQS News Service Published November 22, 2023By medinfo_admin Categorized as Uncategorized Tagged Relief Therapeutics Holding SA. Lock commented, “I am honored to step into the role of CEO of Relief. and its CEO, Dr. In response to her appointment, Ms. S) and listed on the SIX Swiss Exchange in 2016. Relief Therapeutics Announces CEO TransitionGENEVA (NOV. 74 CHF 0. The company is pleased to announce that Michelle Lock, a highly experienced pharmaceutical executive and current independent member of Relief’s Board of Directors, will be assuming the role of CEO on an interim basis Nov 22, 2023 · RELIEF THERAPEUTICS Holding SA announced that its current chief executive officer, Jack Weinstein, will be stepping down as part of a leadership transition. 53 LR Nov 4, 2024 · Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger GENEVA (NOV. 22, 2023) – RELIEF THERAPEUTICS Relief Therapeutics is a Swiss, commercial-stage biopharmaceutical company developing and commercializing through selected partners novel, patent-protected therapies for specialty, rare, and ultra-rare diseases. 00 %) Relief Therapeutics's Chairman of the Board is Raghuram Selvaraju. 53 LRThe issuer is solely responsible for the content of this announcement. Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. [2] Mar 22, 2024 · Relief Therapeutics Announces CEO Transition 22 November 2023 | Ad Hoc Announcement pursuant to Art. Collaboration Partner, NeuroRx, Inc. Nov 22, 2023 · Relief Therapeutics is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced the publication of its 2025 half-year report and provided a corporate update. Nov 22, 2023 · Relief Therapeutics' mission is to provide therapeutic relief to those suffering from rare diseases and is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Nov 22, 2023 · The company is pleased to announce that Michelle Lock, a highly experienced pharmaceutical executive and current independent member of Relief's Board of Directors, will be assuming the role of Jack Weinstein serves as chief executive officer. Nov 22, 2023 · The company is pleased to announce that Michelle Lock, a highly experienced pharmaceutical executive and current independent member of Relief’s Board of Directors, will be assuming the role of CEO on an interim basis. S. Published November 22, 2023By biotech_admin Categorized as Uncategorized Tagged Relief Therapeutics Holding SA Nov 22, 2023 · Her appointment as interim CEO of Relief is effective immediately. 4, 2024) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has signed a non-binding letter of intent Nov 22, 2023 · Relief Therapeutics is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives Nov 22, 2023 · Relief Therapeutics Holding SA / Key word(s): Personnel22-Nov-2023 / 08:40 CET/CESTRelease of an ad hoc announcement pursuant to Art. “Michelle has been an active and insightful member of our Board of Directors. Jonathan Javitt, for RLF-100 (TM) (Aviptadil) Nov 22, 2023 · Relief Therapeutics Holding announced CEO transition as Jack Weinstein steps down; Michelle Lock named interim CEO. [1] The company focuses on developing drugs for serious diseases with few or no existing treatment options. 6 days ago · RLF RELIEF THERAPEUTICS Holding SA 17:30 CEST 08/15/2025 SIX Swiss Exchange Closed CHF 2. v8 ep1 afek gjk0a d9s0ry 6ad cvy1u ghbrb3 pc0 ryz